Timothy Eugene Sullivan
CIK 1707000 · Chief Financial Officer · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
60
Lifetime Open-Market Net
-$10.44M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Financial Officer | 0 | $41.03 | $0 | -$10.44M | 41 | 2026-05-14 |
Recent Filings · Page 3 of 6
60 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −1,730 | -$51.8K | EDGAR |
| 2025-01-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,170 | -$62.3K | EDGAR |
| 2025-01-13 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −2,209 | -$63.4K | EDGAR |
| 2025-01-03 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Exer (M) | +11,096 | $154.8K | EDGAR |
| 2024-04-19 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Gift (G) | — | $0 | EDGAR |
| 2024-04-02 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | — | -$194.5K | EDGAR |
| 2024-04-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −4,000 | -$234.6K | EDGAR |
| 2024-03-05 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | — | -$319.2K | EDGAR |
| 2024-03-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −6,000 | -$379.3K | EDGAR |
| 2024-02-13 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,431 | -$97.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.